GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection
The National Health Care Institute has completed its assessment whether the medicinal product lenacapavir (Sunlenca®) can be included in the Medicine Reimbursement System (GVS). This product is indicated for the treatment of adults with a multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen. The National Health Care Institute advises the Minister of Health, Welfare and Sport to include lenacapavir (Sunlenca®) on List 1B of the Medicine Reimbursement System (GVS), imposing List 2 conditions. Lenacapavir has been evaluated via the parallel procedure with the Medicines Evaluation Board (MEB). In October 2022, the Minister decided to adopt the advice of the National Health Care Institute.
Indication for which reimbursement is requested
Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of adults with a multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen.
National Health Care Institute's advice
The National Health Care Institute concludes that lenacapavir (Sunlenca®) can be included on List 1B and List 2 of the Health Insurance Regulation.
This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.